Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE (2015) Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med 162(1):46–54
Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006) Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45(1):50–52
Canada, D.o.J., Acts, Regulations,Health. Marihuana Medical Access Regulations (SOR/2001-227),P.C. 2001–1146 2001-06-14. http://lois-laws.justice.gc.ca/eng/regulations/SOR-2001-227/FullText.html . Accessed 01 June 2015
Cohen J (1988) Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Hillsdale
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3(9):771–784
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9(2):105–121
Fayers PM, Hays RD (2014) Don’t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Qual Life Res 23(1):1–4
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162–173
Fitzcharles MA, Jamal S (2015) Expanding medical marijuana access in Canada: considerations for the rheumatologist. J Rheumatol 42(2):143–145
Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX et al (2013) 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 18:119–126
Fitzcharles MA, Clauw DJ, Ste-Marie PA, Shir Y (2014) The dilemma of medical marijuana use by rheumatology patients. Arthritis Care Res (Hoboken) 66:797–801
Fiz J, Durán M, Capellà D, Carbonell J, Farré M (2011) Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One 6(4):e18440
Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N (2005) Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 29:49–52
Guindon J, Hohmann AG (2009) The endocannabinoid system and pain. CNS Neurol Dis Drug Targets 8:403–421
Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B (2013) Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 1:CD010292
Häuser W, Walitt B, Fitzcharles MA, Sommer C (2014) Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther 16:201
Häuser W, Klose P, Welsch P, Petzke F, Nothacker M, Kopp I (2015) [Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain]. Schmerz 29(1):8–34
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87(5):1932–1936
Higgins JPT, Green S, Higgins JPT, Altman DG, Sterne JAC (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org
Hillard CJ, Weinlander KM, Stuhr KL (2012) Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204:207–229
Hoch E, Bonnet U, Thomasisus R, Ganzer F, Havemann-Reinecke U, Preuss UW (2015) Risks associated with the non-medical use of cannabis. Dtsch Arztebl Int 112:271–278
Landry T, Fitzcharles MA, Ste-Marie PA, Shir Y (2014) Efficacy and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Rheum 66(11):S110–S111
Lee MC, Ploner M, Wiech K, Bingel U et al (2013) Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154:124–134
Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106(48):20270–20275
Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72(5):735–744
Malfait AM, Gallily R, Sumariwalla PF et al (2000) The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561–9566
Moher D, Liberati A, Teztlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med 51:1–7
Moore RA, Barden J, Derry S, McQuay HJ (2008) Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA (eds) Systematic reviews in pain research: methodology refined. IASP Press, Seattle, pp 15–24
Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ (2010a) Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 149(2):360–364
Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S et al (2010b) “Evidence” in chronic pain—establishing best practice in the reporting of systematic reviews. Pain 150(3):386–389
National Pain Foundation (2014) Marijuana rated most effective for treating fibromyalgia. www.thenationalpainfoundation.org/pain-news.php . Accessed 1 April 2015
Office of the Information Commissioner of Canada, Information request (ATI 2013-00282) under the Access to Information Act. 2013. Accessed 01.06.2015
Petzke F, Welsch P, Klose P, Schaefert R, Sommer C, Häuser W (2015) [Opioids in chronic low back pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration]. Schmerz 29(1):60–72
Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W (2006) [Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain—a randomized controlled trial]. Wien Klin Wochenschr 118(11–12):327–335
Richardson D, Pearson RG, Kurian N, Latif ML, Garle MJ, Barrett DA, Kendall DA, Scammell BE, Reeve AJ, Chapman V (2008) Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 10(2):R43
Russo EB (2008) Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 29:192–200
Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W (2015) [Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration]. Schmerz 29(1):47–59
Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R (2006) Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 27:1269–1276
Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9(2):164–173
Ste-Marie PA, Fitzcharles MA, Gamsa A, Ware MA, Shir Y (2012) Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia. Arthritis Care Res (Hoboken) 64(8):1202–1208
The Nordic Cochrane Centre, The Cochrane Collaboration (2014) Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen
Üçeyler N, Häuser W, Sommer C (2011) Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 12:245
Üçeyler N, Sommer C, Walitt B, Häuser W (2013) Anticonvulsants for fibromyalgia. Cochrane Database Syst Rev 10:CD010782
van Houdenhove B, Egle UT (2004) Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together. Psychother Psychosom 73(5):267–275
Volkow ND, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 371(9):879
Von Korff M (2013) Opioids for chronic musculoskeletal pain: putting patient safety first. Pain 154(12):2583–2585
Ware MA, Adams H, Guy GW (2005) The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 3:291–295
Ware MA, Fitzcharles MA, Joseph L, Shir Y (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 10(2):604–610
Weber J, Schley M, Casutt M, Gerber H et al (2009) Tetrahydrocannabinol (Delta 9-THC) treatment in chroniccentral neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anesthesiol Res Pract pii: 827290
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313(24):2456–2473
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P et al (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610